3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Blood Specimen Collection
6
pembrolizumab
2
fluciclovine F-18
2
Surveys and Questionnaires
2
Preoperative Exercise
2
Magnetic Resonance Imaging
2
Exercise
2
Cryosurgery
2
Bevacizumab
2
tislelizumab
1
neratinib
1
imetelstat
1
daratumumab
1
atezolizumab
1
abiraterone
1
Waiting Lists
1
Videotape Recording
1
Urine Specimen Collection
1
Triamcinolone Acetonide
1
Transcutaneous Electric Nerve Stimulation
1
Tomography, X-Ray Computed
1
Thoracic Surgical Procedures
1
TIC10 compound
1
Sulfonylurea Compounds
1
Standard of Care
1
Specimen Handling
1
Sodium-Glucose Transporter 2 Inhibitors
1
Serologic Tests
1
Sequence Analysis, RNA
1
S-Adenosylmethionine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
1 year
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled